Our Pricing

Which Is Safer: Wegovy or Mounjaro? A Clinical Safety Comparison

Published: 10 September 2026

When deciding which is safer Wegovy or Mounjaro, both medications demonstrate strong safety profiles in clinical trials, though they differ in mechanism, side effect frequency, and cardiovascular outcomes. Wegovy (semaglutide) and Mounjaro (tirzepatide) are both injectable GLP-1 receptor agonists licensed by the MHRA for weight management, but understanding their distinct safety data helps patients and prescribers make evidence-based choices. This guide examines head-to-head safety evidence, real-world adverse event rates, and prescriber considerations to answer which is safer for UK patients.

Which Is Safer Wegovy or Mounjaro: Overview of Clinical Safety Data

To determine which is safer Wegovy or Mounjaro, we must examine the pivotal clinical trials that led to their MHRA approval. Wegovy's safety profile is established through the STEP trial programme, which enrolled over 4,500 participants across multiple studies, reporting adverse event rates, discontinuation rates, and cardiovascular outcomes [1]. Mounjaro's safety data comes primarily from the SURMOUNT trials for weight loss and SURPASS trials for type 2 diabetes, involving more than 6,600 participants in weight management studies [2].

Both medications share a similar side effect profile dominated by gastrointestinal symptoms—nausea, vomiting, diarrhoea, and constipation—which are typically mild to moderate and diminish over time [1][2]. In the STEP 1 trial, 74% of Wegovy participants experienced at least one adverse event, compared to 65% in the placebo group, with gastrointestinal issues accounting for the majority [1]. In SURMOUNT-1, 79% of Mounjaro participants reported adverse events, with dose-dependent increases in gastrointestinal symptoms [2]. Discontinuation rates due to adverse events were 4.3% for Wegovy in STEP 1 and ranged from 4.3% to 6.2% for Mounjaro across SURMOUNT trials, suggesting comparable tolerability when properly titrated.

Serious adverse events occurred in 9.8% of Wegovy participants versus 6.4% in placebo groups, though most were not deemed medication-related [1]. For Mounjaro, serious adverse events ranged from 5.2% to 7.1% across doses in SURMOUNT-1, comparable to the 5.0% placebo rate [2]. Neither medication showed signals of major organ toxicity, and both demonstrated acceptable safety in participants with cardiovascular risk factors, though Wegovy has more extensive cardiovascular outcomes data through the SELECT trial [3].

Gastrointestinal Safety: Which Is Safer Wegovy or Mounjaro for Digestive Tolerability?

Gastrointestinal side effects are the most common reason patients ask which is safer Wegovy or Mounjaro. Both medications slow gastric emptying and modulate appetite through GLP-1 receptor pathways, leading to predictable digestive symptoms during dose escalation. In STEP trials, nausea occurred in 44% of Wegovy participants versus 17% in placebo, vomiting in 24% versus 6%, and diarrhoea in 30% versus 16% [1]. Mounjaro's SURMOUNT-1 data showed nausea in 31-43% of participants (dose-dependent), vomiting in 17-26%, and diarrhoea in 23-27% [2].

The key difference lies in Mounjaro's dual GLP-1/GIP receptor mechanism, which some researchers hypothesise may offer slightly better gastrointestinal tolerability at equivalent weight loss doses, though this remains debated [4]. In practice, both medications require slow dose titration over 16-20 weeks to minimise digestive upset. Cured Pharmacy's clinical team advises patients to start with the lowest dose, increase gradually as prescribed, and take medication with food to reduce nausea. Most gastrointestinal symptoms resolve within 4-8 weeks of maintaining a stable dose.

Rare but serious gastrointestinal complications include pancreatitis and gallbladder disease. Pancreatitis occurred in <0.2% of participants in both STEP and SURMOUNT trials, with no clear difference between Wegovy and Mounjaro [1][2]. Cholelithiasis (gallstones) risk is elevated with rapid weight loss from any cause, and both medications carry warnings for biliary disease. Patients with a history of pancreatitis or severe gallbladder disease should discuss these risks with their prescriber during the online consultation at Cured Pharmacy.

Managing Gastrointestinal Side Effects with Wegovy and Mounjaro

Regardless of which is safer Wegovy or Mounjaro in theory, practical tolerability depends on individualised dose management. UK prescribers recommend eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and never skipping the gradual dose escalation schedule. If nausea persists beyond the first month at a stable dose, prescribers may slow the titration or maintain a lower maintenance dose. Both medications allow flexible dosing adjustments, and treatment should always be supervised by a UK-registered clinician.

Cardiovascular Safety: Which Is Safer Wegovy or Mounjaro for Heart Health?

Cardiovascular safety is a critical consideration when evaluating which is safer Wegovy or Mounjaro, particularly for patients with existing heart disease or multiple risk factors. Wegovy has the most robust cardiovascular outcomes data through the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in participants with pre-existing cardiovascular disease who received semaglutide 2.4 mg versus placebo [3]. This landmark finding led to expanded indications and reinforced Wegovy's safety profile in high-risk populations.

Mounjaro does not yet have dedicated cardiovascular outcomes trial data for its weight loss indication, though the SURPASS-CVOT trial is ongoing for tirzepatide in type 2 diabetes patients. Existing SURPASS data show favourable effects on cardiovascular risk markers—significant reductions in systolic blood pressure (average 7-10 mmHg), improvements in lipid profiles, and reductions in inflammatory markers [2][4]. These surrogate markers suggest potential cardiovascular benefit, but direct outcomes data comparable to SELECT are not yet available for Mounjaro in weight management populations.

Both medications carry warnings about potential increases in heart rate (average 2-4 bpm elevation) and should be used cautiously in patients with arrhythmias or uncontrolled hypertension [1][2]. Neither medication is contraindicated in cardiovascular disease, and both are considered safer than older weight loss agents like sibutramine, which was withdrawn due to cardiovascular risks. For patients with established heart disease seeking weight loss treatment, Wegovy currently has stronger evidence for cardiovascular safety, though Mounjaro remains a viable option subject to prescriber assessment.

Thyroid Safety and Cancer Risk: Which Is Safer Wegovy or Mounjaro?

A common concern when comparing which is safer Wegovy or Mounjaro involves thyroid C-cell tumours, as both medications carry black box warnings based on rodent studies showing increased medullary thyroid carcinoma (MTC) risk at high doses [1][2]. In rats and mice, GLP-1 receptor agonists caused dose-dependent thyroid C-cell hyperplasia and adenomas, though no causal link has been established in humans after over a decade of post-marketing surveillance.

Neither Wegovy nor Mounjaro is approved for use in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a strict contraindication for both medications. In clinical trials involving tens of thousands of participants, no cases of MTC were attributed to semaglutide or tirzepatide, and thyroid tumour rates were comparable to placebo [1][2]. The MHRA and FDA continue to monitor post-marketing data, and current evidence does not suggest elevated human thyroid cancer risk at therapeutic doses.

Routine thyroid monitoring is not required for patients without risk factors, though prescribers may check baseline thyroid function if clinically indicated. Patients should report symptoms of thyroid tumours—neck lump, persistent hoarseness, difficulty swallowing, or shortness of breath—immediately, though these are exceedingly rare. From a thyroid safety perspective, Wegovy and Mounjaro carry equivalent theoretical risk based on their shared GLP-1 mechanism, with no evidence favouring one over the other in human populations.

Other Malignancy Considerations for Wegovy and Mounjaro

Beyond thyroid concerns, large-scale trials and post-marketing data have not identified increased cancer risk with either medication [3][4]. The SELECT trial's extended follow-up showed no signal for increased malignancy with semaglutide, and SURMOUNT data similarly showed no cancer signal for tirzepatide [2][3]. Both medications are considered safe from an oncology perspective, though patients with active malignancy should discuss treatment timing with their oncologist and prescriber.

Hypoglycaemia and Metabolic Safety: Which Is Safer Wegovy or Mounjaro?

Hypoglycaemia risk is low with both Wegovy and Mounjaro when used as monotherapy for weight loss, as neither medication directly stimulates insulin secretion in the absence of glucose [1][2]. In STEP trials, hypoglycaemia rates with Wegovy were comparable to placebo (<1%) in participants without diabetes [1]. Similarly, SURMOUNT trials reported minimal hypoglycaemia with Mounjaro in non-diabetic participants [2]. This distinguishes GLP-1 receptor agonists from older diabetes medications like sulphonylureas, which carry significant hypoglycaemia risk.

However, patients using Wegovy or Mounjaro alongside insulin or sulphonylureas for type 2 diabetes require dose adjustments to prevent hypoglycaemia. UK prescribing guidelines recommend reducing insulin doses by 20-30% when initiating GLP-1 therapy and closely monitoring blood glucose during titration. Mounjaro's dual GLP-1/GIP mechanism may offer slightly more potent glucose-lowering effects in diabetic patients, but this does not translate to higher hypoglycaemia risk in weight loss populations without diabetes [4].

Both medications improve metabolic parameters beyond glucose control—reductions in HbA1c (in diabetic patients), improvements in insulin sensitivity, and favourable lipid changes [2][4]. Neither medication causes clinically significant electrolyte disturbances, liver enzyme elevations, or renal impairment in participants with normal baseline function. Patients with moderate renal impairment (eGFR 30-59 mL/min) can use both medications with standard dosing, though those with severe renal impairment should be monitored closely or consider alternative treatments.

Real-World Safety and Prescriber Consensus: Which Is Safer Wegovy or Mounjaro in UK Practice?

When UK prescribers evaluate which is safer Wegovy or Mounjaro, they consider not only trial data but also real-world evidence, patient comorbidities, and individual tolerability. Post-marketing surveillance data from the MHRA Yellow Card scheme shows similar adverse event reporting rates for both medications, with gastrointestinal symptoms dominating reports and no unexpected safety signals emerging [5]. Wegovy has been available longer in the UK (approved June 2022), giving it a larger real-world safety dataset, while Mounjaro (approved November 2023 for weight loss) is accumulating evidence rapidly.

Prescriber consensus suggests that neither medication is categorically safer—rather, safety depends on patient-specific factors. Wegovy may be preferred for patients with established cardiovascular disease due to SELECT trial data, while Mounjaro may suit patients who experienced intolerable gastrointestinal side effects on Wegovy, as the dual GIP/GLP-1 mechanism may offer different tolerability [3][4]. Both medications require the same contraindication screening (MTC/MEN 2 history, pregnancy, severe gastroparesis) and similar monitoring during treatment.

At Cured Pharmacy, our UK-registered prescribers conduct thorough online consultations to assess medical history, current medications, and individual risk factors before recommending Wegovy or Mounjaro. Wegovy is available from £124.99, and Mounjaro from £124.99, with all patients receiving £20 off their first order using code Weightlossnew. Treatment choice is always individualised, and patients can discuss their safety concerns directly with our clinical team during the 3-minute online assessment. Both medications are dispensed with full patient information leaflets and access to ongoing prescriber support throughout treatment.

Switching Between Wegovy and Mounjaro: Safety Considerations

Patients who experience intolerable side effects or inadequate weight loss on one medication may switch to the other under prescriber guidance. Switching from Wegovy to Mounjaro (or vice versa) requires a washout period of at least one week and restarting at the lowest dose of the new medication to avoid compounded side effects [5]. UK prescribers at Cured Pharmacy can advise on safe switching protocols during follow-up consultations, ensuring continuity of care and optimal safety throughout weight loss treatment.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 10 September 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 10 September 2026]
3. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 10 September 2026]
4. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 10 September 2026]
5. Medicines and Healthcare products Regulatory Agency. (2024). Yellow Card reporting: GLP-1 receptor agonists safety update. GOV.UK. [accessed 10 September 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.